Prospective Observational Study Collecting Data on Thoracic Cancers from Diagnosis to Treatment Outcomes

What this Trial Is About

Survival after a cancer diagnosis depends heavily on factors such as tumor size, lymph node involvement, and presence of metastases. However, individual outcomes vary greatly due to a mix of molecular, biochemical, genetic, clinical, and environmental influences. This study focuses on patients with thoracic malignancies, such as lung cancer, aiming to understand how these diverse factors affect tumor recurrence and mortality across all stages of disease. This research is a prospective observational cohort study collecting detailed data from diagnosis until death for patients with thoracic cancers. After informed consent, it gathers medical history, clinical parameters, imaging, pathology, tumor details, treatments, outcomes, hospital stays, and adverse events. Additional data on quality of life, work ability, imaging, blood, and tumor tissue may be collected with separate consent. The study also links data with a national cancer registry every six months to enrich information. Participants will be followed long-term, with questionnaires on quality of life completed at regular intervals. Blood samples and tissue obtained during routine care may be collected for research purposes without extra procedures. Researchers will monitor progression-free survival up to 10 years, along with disease-free survival, overall survival, and patient-reported quality of life. The study aims to improve understanding of real-world outcomes and support future personalized treatment innovations for thoracic cancers.

Prospective Data Collection Initiative on Thoracic Malignancies